Related Experiment Video

Updated: Jun 2, 2026

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
10:28

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

Dichloroacetate inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells

Serena Vella1, Matteo Conti, Roberta Tasso

  • 1Oncology, Biology, and Genetics Department (DOBiG), University of Genoa, Genoa-Italy.

International Journal of Cancer
|May 11, 2011
PubMed

Insights

Dichloroacetate (DCA) shows unexpected anticancer effects against neuroblastoma, selectively targeting highly malignant cells. This finding suggests DCA

Area of Science:

  • Biochemistry
  • Oncology
  • Mitochondrial Medicine

Background:

  • Dichloroacetate (DCA) is a small, water-soluble molecule investigated for cancer therapy due to its specific mitochondrial action.
  • DCA was previously considered ineffective against neuroblastoma (NB) due to presumed lack of mitochondrial anomalies in NB cells.
  • Neuroblastoma exhibits cellular heterogeneity in metabolism, phenotype, and malignancy.

Purpose of the Study:

  • To investigate the anticancer effects of Dichloroacetate (DCA) on neuroblastoma (NB) cells.
  • To determine if DCA's efficacy varies across different NB cell types based on their malignancy.
  • To assess the potential of DCA as a therapeutic agent for neuroblastoma.

Main Methods:

  • Treatment of neuroblastoma cell lines with Dichloroacetate (DCA).
  • Analysis of DCA's effect on tumor cell growth and viability.
  • Differential assessment of DCA's impact on highly malignant versus differentiated NB cells.

Main Results:

  • Dichloroacetate (DCA) demonstrated an unexpected anticancer effect on neuroblastoma (NB) tumor cells.
  • The anticancer effect of DCA was selectively observed in highly malignant NB cells.
  • Differentiated, less malignant NB cells were found to be refractory to DCA treatment.

Conclusions:

  • DCA exhibits selective anticancer activity against aggressive neuroblastoma cells.
  • The findings challenge previous assumptions about DCA's ineffectiveness in neuroblastoma.
  • Further investigation into DCA's therapeutic potential for neuroblastoma is warranted.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...